Cempra Announces Proposed Public Offering of $175 Million of Common Stock
January 05, 2016 16:10 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Doses Initial Patient in Phase 2 Clinical Trial of Solithromycin in NASH
January 05, 2016 07:00 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Enters Into a CRADA With the NIAID and Expands the Phase 3 Solithromycin Clinical Trial in Urogenital Gonorrhea to Include Additional Female Patients and Adolescents
December 22, 2015 16:05 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Dec. 22, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Doses First Patient in Phase 3 Clinical Trial of Taksta(TM) in Acute Bacterial Skin and Skin Structure Infections
December 08, 2015 07:00 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Dec. 8, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company developing antibiotics to meet critical medical needs in the treatment of...
Cempra to Present Anti-NASH Data for Solithromycin at The Liver Meeting(R) 2015
November 11, 2015 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present at Two Upcoming Investor Conferences
November 10, 2015 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present Solithromycin Oral Data at CHEST 2015
October 23, 2015 09:24 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Oct. 23, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Reports Third Quarter 2015 Financial Results and Provides Corporate Update
October 22, 2015 07:00 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Oct. 22, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Report Third Quarter 2015 Financial Results
October 19, 2015 08:00 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Oct. 19, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Announces Positive Topline Phase 3 Clinical Results for Intravenous Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
October 16, 2015 07:00 ET
|
Melinta Therapeutics, Inc.
Solithromycin Met All FDA Primary Objectives of Non-Inferiority Compared to Moxifloxacin
Two Phase 3 Trials Required by the FDA and the EMA for CABP Regulatory Filings Now Complete
Rolling NDA...